Menopause treatment options: HRT, non-hormonal options, and how to choose

What actually works for perimenopause relief?

That question deserves a direct answer, not a caveat spiral. The short version: hormone therapy works best, non-hormonal prescription options are a real alternative when HRT isn't suitable, and lifestyle changes help but rarely carry the full load alone. The longer version is what the rest of this guide is for.

The Menopause Society's 2022 hormone therapy position statement — reviewed and endorsed by more than 20 medical organizations — concludes that for women under 60, or within 10 years of their final menstrual period, the benefits of hormone therapy outweigh the risks when used to treat menopausal symptoms. That's a consensus, not a fringe opinion. The Women's Health Initiative study from 2002 spooked a generation of doctors and patients, but later analysis made clear that the risks it found applied mainly to older women starting HRT more than a decade after menopause — not to the typical perimenopausal woman in her mid-40s or early 50s.

At the same time, HRT isn't one-size-fits-all, and it isn't right for everyone. The full landscape of options — which form of HRT, which non-hormonal alternatives, and which lifestyle foundations actually move the needle — is worth understanding before you have that first appointment.

Hormone therapy: patches, gels, pills, and IUDs — what's the difference?

HRT for perimenopause and menopause typically involves estrogen, progesterone (or a synthetic progestin), or both. The form and route of delivery matter more than many women realize.

Transdermal estrogen (patches, gels, sprays)

Patches, gels, and sprays deliver estradiol directly through the skin, bypassing the liver. That distinction carries a meaningful safety advantage: unlike oral estrogen, transdermal estrogen does not appear to increase the risk of blood clots (venous thromboembolism), and stroke risk is also not elevated. NICE and The Menopause Society both flag this as the preferred route for women at higher baseline VTE risk — including those with a BMI over 30 or a strong family history of clotting. For most women, transdermal is simply a lower-risk starting point.

Oral estrogen (pills)

Oral estrogen is convenient and widely available, but it passes through the liver on its way into your bloodstream. That first-pass metabolism raises clotting factors slightly, which is why the VTE risk is higher with pills than with patches or gels. It's still a reasonable option for many women — just one that requires a more careful conversation for those with specific risk factors.

Progesterone and progestins — why they matter if you have a uterus

Any woman who still has a uterus needs a progestogen alongside estrogen — estrogen alone can cause the uterine lining to thicken over time. That progestogen can come as an oral micronized progesterone pill (bioidentical), a synthetic progestin tablet, or a hormonal IUD such as the Mirena. The levonorgestrel-releasing IUD is particularly useful during perimenopause: it provides endometrial protection locally (so the systemic progestogen load is very low), and it can manage the irregular, heavy bleeding that many women experience in their 40s. Our guide to IUDs in perimenopause covers that option in depth.

Low-dose combined hormonal contraceptives

For women in their early-to-mid 40s who still need contraception, low-dose combined oral contraceptives can serve double duty: they suppress the hormonal swings of perimenopause while providing pregnancy prevention. They're not the right tool for every woman, and they carry their own risk profile — but they're worth discussing if contraception is still on the agenda.

Non-hormonal prescriptions: what are the real options?

The non-hormonal category has grown substantially. If HRT isn't an option — because of a personal or family history of hormone-receptor-positive breast cancer, active VTE, severe liver disease, or simply personal preference — there are prescription alternatives with genuine clinical evidence behind them.

Fezolinetant (Veozah) — the first dedicated non-hormonal hot flash drug

Fezolinetant, sold as Veozah, received FDA approval in May 2023 — the first drug in an entirely new class (NK3 receptor antagonists) approved specifically for menopausal hot flashes. It works by targeting KNDy neurons in the hypothalamus, which play a central role in thermoregulation. The SKYLIGHT clinical trials showed fezolinetant reduced moderate-to-severe hot flash frequency by roughly 60% compared with placebo.

There is a critical safety update to know: in December 2024, the FDA added a boxed warning to Veozah after post-marketing reports of rare but serious liver injury. Current prescribing guidance requires liver function testing before starting the drug and monthly for the first two months, then at months three, six, and nine of treatment. Veozah should not be used in patients with cirrhosis or severe kidney disease, and it cannot be combined with CYP1A2 inhibitors. If you're considering it, that monitoring schedule is non-negotiable. Our full Veozah review covers the safety picture in more detail.

SSRIs and SNRIs — antidepressants that also cool hot flashes

Certain antidepressants reduce vasomotor symptoms independently of their effect on mood. The NAMS 2023 nonhormone therapy position statement lists SSRIs and SNRIs at Level I evidence for vasomotor symptom relief. Paroxetine (a low-dose salt formulation, Brisdelle) is the only SSRI with an FDA approval specifically for hot flashes; others including escitalopram, venlafaxine, and desvenlafaxine are used off-label. The effect is real but more modest than HRT — they work best for women whose primary concern is hot flashes and who have a contraindication to hormones, or who are also managing mood changes alongside their physical symptoms.

Gabapentin — an option for nighttime sweating and sleep disruption

Gabapentin, an anti-seizure medication, has randomized trial data showing it reduces hot flash frequency and severity. NAMS also gives it Level I evidence in the 2023 statement. Its sedating quality makes it particularly useful for women whose worst symptoms hit at night, disrupting sleep. Side effects to weigh include dizziness, drowsiness, and weight gain — the sedation that helps at bedtime can interfere with daytime function if dosing isn't carefully titrated.

What about vaginal symptoms — are those treated differently?

Yes, and this is a point many women (and some clinicians) miss. Genitourinary syndrome of menopause (GSM) — which covers vaginal dryness, irritation, urinary urgency, and pain with sex — doesn't always respond to systemic HRT alone, and it can persist long after hot flashes resolve. First-line treatment for mild symptoms is non-hormonal: lubricants for symptom relief and vaginal moisturizers used regularly for maintenance.

For symptoms that don't respond to those, low-dose local vaginal estrogen (cream, ring, tablet, or gel) is effective and delivers very little estrogen into the bloodstream. NAMS and the American Urological Association both recommend vaginal therapy as the first-line pharmacologic option for GSM. Two non-estrogen alternatives are also available: vaginal DHEA (Intrarosa) and ospemifene (Osphena), an oral pill that acts on vaginal tissue. Clinicians are no longer required to perform endometrial surveillance solely because a patient uses low-dose vaginal estrogen — a meaningful quality-of-life simplification.

CBT, hypnosis, and the mind-body approaches — what's the evidence?

Cognitive behavioral therapy (CBT) has solid evidence for menopausal insomnia and for reducing the distress caused by hot flashes — even when it doesn't reduce their frequency as dramatically as medications do. A systematic review published in 2025 found CBT significantly improves health-related quality of life and alleviates psychological and sleep-related symptoms. The 2024 NICE menopause guideline recommends CBT as an option alongside HRT, or for women who cannot or prefer not to take hormone therapy.

Clinical hypnosis has emerged as a notable option specifically for hot flash frequency and severity, with scoping reviews suggesting a larger effect size than CBT for that particular symptom. CBT-I (for insomnia) is recognized as the evidence-based first-line treatment for chronic insomnia regardless of menopause, which is important context — the perimenopause insomnia guide covers the sleep side of this in full.

Do lifestyle changes actually help perimenopause symptoms?

They help — but their power is real and limited at the same time. Exercise is the most consistently supported lifestyle intervention: regular aerobic and strength training can reduce the intensity of vasomotor symptoms, improve mood, protect bone density, and help with the body-composition shifts that often arrive during perimenopause. Increasing activity by even a modest amount moves the needle.

Diet matters for long-term health outcomes in this life phase — cardiovascular risk, insulin sensitivity, bone health all respond to nutritional choices. Reducing alcohol and caffeine can directly reduce hot flash frequency for some women. Prioritizing sleep hygiene matters because poor sleep worsens nearly every other symptom. What lifestyle approaches cannot do, reliably, is replace medical treatment for moderate-to-severe vasomotor symptoms or GSM. Think of them as a foundation that makes whatever treatment you choose work better. The perimenopause diet guide has specifics on what the evidence actually supports.

• Aerobic exercise: linked to reduced hot flash intensity and better mood
• Strength training: helps preserve muscle mass and bone density during the transition
• Reducing alcohol and caffeine: can lower hot flash frequency for some women
• Sleep hygiene: crucial because sleep loss amplifies every other symptom
• Stress management (CBT, mindfulness, hypnosis): evidence-backed, especially for insomnia and mood

Who should not take HRT?

Systemic hormone therapy has real contraindications — and knowing them helps clarify who the non-hormonal options are actually designed for. Current guidance identifies the following as contraindications to systemic HRT:

• Personal history of hormone-receptor-positive breast cancer
• Active or recent venous thromboembolism (blood clot)
• Severe active liver disease
• Unexplained vaginal bleeding
• Certain cardiovascular conditions (a shared decision-making conversation is essential here)

Breast cancer survivors in particular often live with significant vasomotor symptoms and have historically had very limited options. Fezolinetant's non-hormonal mechanism makes it a candidate for this group — though the boxed liver warning means the risk-benefit conversation is still necessary. SSRIs, SNRIs, gabapentin, and CBT are all hormone-free and appropriate for most women in this situation.

How does telemedicine for menopause actually work — and is it enough?

A 2025 survey found that nearly 71% of women between 45 and 60 said their primary care doctor didn't adequately prepare them for menopause or offer a thorough discussion of treatment options. That gap is precisely what menopause-focused telehealth was built to fill.

Telemedicine for menopause typically works in one of two models. The first is an asynchronous questionnaire plus clinician review — you fill out a detailed intake, a licensed provider reviews your history and can prescribe if appropriate, and medications ship directly to your door. The second model uses live video appointments with a practitioner who specializes in menopause care. Both can result in a legitimate prescription. Neither replaces the need for a clinician who takes your full health history seriously.

The major platforms each have a distinct focus. Midi Health operates as a full virtual clinic for women 40+, accepts major insurance plans including BlueCross, Aetna, and United, and offers both perimenopause and menopause care across all 50 states. Alloy and Winona focus exclusively on menopause hormone therapy through a more streamlined questionnaire-and-prescription model, with medications shipped directly to you — pricing for both starts around $120 per month, though your specific regimen will determine the actual cost.

What telemedicine does well: it removes the barrier of finding a local specialist (menopause-literate providers are genuinely scarce), it fits around a busy schedule, and it often delivers care faster than waiting for a GYN appointment. What to verify: whether the platform can handle your full picture (complex medical history, labs, follow-up), and which states it operates in.

How do you actually choose between all these options?

The right treatment depends on three things: your symptom profile, your health history, and your own priorities. A provider who takes the time to understand all three is non-negotiable.

• Moderate-to-severe hot flashes and night sweats with no HRT contraindication: systemic hormone therapy (transdermal if you have any VTE risk factors) is the first-line recommendation from every major guideline body
• Hot flashes and a history of ER/PR-positive breast cancer: non-hormonal options — fezolinetant, SSRIs/SNRIs, gabapentin, CBT — are where the conversation starts
• Vaginal dryness, discomfort, or urinary symptoms: low-dose local vaginal estrogen is effective even for women who cannot use systemic HRT, and does not carry the same systemic risks
• Sleep as the primary problem: CBT-I has the strongest evidence base for chronic insomnia; if hot flashes are driving the wake-ups, treating those (with any of the above) typically helps sleep too
• Mood changes alongside physical symptoms: SSRIs/SNRIs address both, making them a logical first choice when mood is part of the picture
• Perimenopause with continued need for contraception: a low-dose combined hormonal contraceptive or a hormonal IUD can manage both

One practical note: symptoms in perimenopause can look similar to thyroid disorders, iron-deficiency anemia, and other conditions. If you haven't had basic labs done, getting them before or alongside starting treatment helps ensure you're treating the right thing. The full perimenopause symptoms list is a useful reference for knowing what fits the hormonal picture and what warrants a second look.

When to see a clinician, not just read a guide

Most perimenopause symptoms are uncomfortable, not dangerous. But some warrant prompt evaluation rather than self-treatment or watchful waiting:

• Heavy bleeding that soaks through a pad or tampon every hour for several hours
• Bleeding between periods, especially if accompanied by pelvic pain
• Postmenopausal bleeding (any bleeding more than 12 months after your last period)
• Sudden severe symptoms — chest pain, one-sided leg pain or swelling — alongside any new HRT
• Symptoms of liver injury while on fezolinetant: fatigue, nausea, yellowing of the skin or eyes, dark urine

If you're noticing significant hair loss alongside other symptoms, that's also worth specifically mentioning to your provider — it can signal thyroid involvement or other nutrient deficiencies that won't resolve with hormone therapy alone.